1. Inhibition of the signaling pathway of syndecan-1 by synstatin: A promising anti-integrin inhibitor of angiogenesis and proliferation in HCC in rats
   Heba A. Metwaly et al, 2018, Archives of Biochemistry and Biophysics CrossRef
2. Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword
   Marion Dajon et al, 2017, Immunobiology CrossRef
3. Anti-tumor Activity of Toll-Like Receptor 7 Agonists
   Huju Chi et al, 2017, Frontiers in Pharmacology CrossRef
4. Innate immunity and hepatocarcinoma: Can toll-like receptors open the door to oncogenesis?
   Jorge André Gomes Lopes, 2016, World Journal of Hepatology CrossRef
5. Toll-like receptors in hepatocellular carcinoma: potential novel targets for pharmacological intervention
   Hai Zou et al, 2016, Expert Opinion on Therapeutic Targets CrossRef
6. Bufalin Suppresses Migration and Invasion of Hepatocellular Carcinoma Cells Elicited by Poly (I:C) Therapy
   Yinglu Feng et al, 2018, OncoImmunology CrossRef
7. Toll-Like Receptors as Therapeutic Targets in Central Nervous System Tumors
   D. M. Abarca-Merlin et al, 2019, BioMed Research International CrossRef
8. Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection
   Mashael R. Al-Anazi et al, 2017, Journal of Immunology Research CrossRef
9. Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists
   Stefano Federico et al, 2020, Journal of Medicinal Chemistry CrossRef
10. Roles of Toll-Like Receptor 3 in Human Tumors
    Xin Zheng et al, 2021, Frontiers in Immunology CrossRef
11. Anandamide restricts uterine stromal differentiation and is critical for complete decidualization
    B.M. Fonseca et al, 2015, Molecular and Cellular Endocrinology CrossRef
12. In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer
    Ayele H. Negussie et al, 2022, Scientific Reports CrossRef
13. Basic understanding and therapeutic approaches to target toll‐like receptors in cancerous microenvironment and metastasis
    Mojtaba Khajeh Alizadeh Attar et al, 2018, Medicinal Research Reviews CrossRef
14. TLR3 Is a Death Receptor Target in Cancer Therapy
    Yann Estornes et al, 2017, TRAIL, Fas Ligand, TNF and TLR3 in Cancer CrossRef